FDA accepts Teva's NDA for albuterol inhaler

The U.S. FDA has accepted for standard review Teva Pharmaceutical Industries' (TEVA +0.9%) NDA for its albuterol multi-dose dry powder inhaler (MDPI) as a treatment for reversible obstructive airway disease and for the prevention of exercise-induced bronchospasm in patients at least 12 years old.

Teva expects a response from the regulator by late Q1 2015.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs